Phenotyping and Genotyping of Duffy Antigen

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05527119

Acronym

DARC

Enrollment

Registered

2022-09-02

Start date

2022-03-11

Completion date

2023-09-11

Last updated

2023-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plasmodium Vivax

Keywords

Malaria, Malaria, Vivax, PvDBP-DARC interaction, Plasmodium vivax, Duffy-negative, Duffy Binding Protein, PvDBP, Duffy Antigen Receptor for Chemokines

Brief summary

Malaria remains the world's leading parasitic endemic. Almost half of the world's population lives in endemic areas. Many at-risk people in African countries remain without access to malaria control. Malaria kills approximately 400,000 people each year, most of whom are children under the age of 5 in Africa. Since 2005, an increasing number of Plasmodium vivax infections have been observed in Duffy-negative populations in South America and Africa, calling into question the essential role of the PvDBP-DARC interaction. The objective of the investigators is therefore to study and understand the invasion pathways used by Plasmodium vivax in Duffy-negative subjects.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Major subjects * with malaria and willing to have their blood samples analyzed for this research

Exclusion criteria

* Subjects refusing to participate in the study

Design outcomes

Primary

Measure	Time frame
Number of blood samples tested (phenotype and genotype).	2 months later

Countries

France

Outcome results